 John Pemberton
Concepts (108)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conjunctiva | 3 | 2024 | 13 | 1.690 |
Why?
| | Eye Enucleation | 2 | 2024 | 11 | 1.470 |
Why?
| | Eyelids | 4 | 2024 | 29 | 1.380 |
Why?
| | Eyelid Neoplasms | 2 | 2022 | 14 | 1.190 |
Why?
| | Conjunctivitis | 1 | 2024 | 6 | 0.890 |
Why?
| | Eyelid Diseases | 1 | 2024 | 12 | 0.870 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2024 | 33 | 0.840 |
Why?
| | Intubation | 2 | 2013 | 6 | 0.810 |
Why?
| | Dacryocystorhinostomy | 2 | 2013 | 10 | 0.810 |
Why?
| | Nasolacrimal Duct | 2 | 2013 | 10 | 0.810 |
Why?
| | Conjunctival Neoplasms | 1 | 2022 | 6 | 0.780 |
Why?
| | Face | 2 | 2019 | 56 | 0.760 |
Why?
| | Blepharoptosis | 2 | 2017 | 13 | 0.670 |
Why?
| | Xanthogranuloma, Juvenile | 1 | 2019 | 4 | 0.640 |
Why?
| | Stents | 2 | 2013 | 351 | 0.640 |
Why?
| | Postoperative Complications | 2 | 2024 | 1066 | 0.630 |
Why?
| | Melanoma | 1 | 2022 | 280 | 0.610 |
Why?
| | Tenon Capsule | 1 | 2017 | 1 | 0.560 |
Why?
| | Blepharoplasty | 1 | 2017 | 9 | 0.560 |
Why?
| | Visual Field Tests | 1 | 2017 | 15 | 0.560 |
Why?
| | Visual Fields | 1 | 2017 | 41 | 0.550 |
Why?
| | Suture Techniques | 1 | 2017 | 60 | 0.540 |
Why?
| | Orbital Neoplasms | 1 | 2017 | 26 | 0.530 |
Why?
| | Ganglioneuroma | 1 | 2016 | 4 | 0.520 |
Why?
| | Neurofibroma, Plexiform | 1 | 2016 | 5 | 0.520 |
Why?
| | Choroid Neoplasms | 1 | 2016 | 6 | 0.520 |
Why?
| | Choroid | 1 | 2016 | 14 | 0.520 |
Why?
| | Neurofibromatosis 1 | 1 | 2016 | 33 | 0.500 |
Why?
| | Naphazoline | 1 | 2015 | 1 | 0.480 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2015 | 21 | 0.470 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2015 | 8 | 0.470 |
Why?
| | Eye Injuries, Penetrating | 1 | 2014 | 11 | 0.440 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2017 | 299 | 0.430 |
Why?
| | Carcinoma, Basal Cell | 1 | 2014 | 40 | 0.420 |
Why?
| | Silicone Elastomers | 1 | 2013 | 9 | 0.410 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2013 | 7 | 0.410 |
Why?
| | Monitoring, Intraoperative | 1 | 2013 | 54 | 0.400 |
Why?
| | Adenocarcinoma | 1 | 2017 | 405 | 0.400 |
Why?
| | Wound Healing | 1 | 2014 | 219 | 0.390 |
Why?
| | Prosthesis Failure | 1 | 2013 | 111 | 0.380 |
Why?
| | Middle Aged | 7 | 2024 | 13014 | 0.360 |
Why?
| | Humans | 16 | 2024 | 52336 | 0.350 |
Why?
| | Skin | 1 | 2014 | 418 | 0.350 |
Why?
| | Female | 11 | 2024 | 28105 | 0.310 |
Why?
| | Skin Neoplasms | 1 | 2014 | 500 | 0.300 |
Why?
| | Diagnosis, Differential | 3 | 2024 | 1044 | 0.300 |
Why?
| | Biopsy | 2 | 2024 | 604 | 0.300 |
Why?
| | Aged, 80 and over | 3 | 2024 | 3391 | 0.290 |
Why?
| | Male | 9 | 2024 | 26696 | 0.290 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 1162 | 0.250 |
Why?
| | Follow-Up Studies | 2 | 2024 | 2268 | 0.250 |
Why?
| | Infant, Newborn | 3 | 2024 | 2826 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2024 | 235 | 0.220 |
Why?
| | Adult | 6 | 2024 | 14139 | 0.210 |
Why?
| | Aged | 3 | 2024 | 10109 | 0.190 |
Why?
| | Adolescent | 2 | 2024 | 6692 | 0.160 |
Why?
| | Inflammation | 1 | 2024 | 642 | 0.160 |
Why?
| | Retrospective Studies | 2 | 2024 | 6578 | 0.160 |
Why?
| | Child | 2 | 2024 | 7157 | 0.150 |
Why?
| | Facial Bones | 1 | 2018 | 18 | 0.150 |
Why?
| | Cleft Lip | 1 | 2018 | 46 | 0.140 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2018 | 16 | 0.140 |
Why?
| | Pseudotumor Cerebri | 1 | 2018 | 25 | 0.140 |
Why?
| | Eye, Artificial | 1 | 2017 | 2 | 0.140 |
Why?
| | Orbital Implants | 1 | 2017 | 4 | 0.140 |
Why?
| | Preoperative Period | 1 | 2017 | 46 | 0.140 |
Why?
| | Cleft Palate | 1 | 2018 | 79 | 0.140 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 22 | 0.140 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2018 | 60 | 0.140 |
Why?
| | Eye Diseases | 1 | 2017 | 29 | 0.140 |
Why?
| | Prosthesis Implantation | 1 | 2017 | 49 | 0.130 |
Why?
| | Postoperative Period | 1 | 2017 | 170 | 0.130 |
Why?
| | Abnormalities, Multiple | 1 | 2018 | 167 | 0.130 |
Why?
| | Biopsy, Fine-Needle | 1 | 2017 | 107 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2017 | 196 | 0.130 |
Why?
| | Young Adult | 2 | 2024 | 4319 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 240 | 0.130 |
Why?
| | Child, Preschool | 1 | 2024 | 4030 | 0.120 |
Why?
| | Miosis | 1 | 2015 | 5 | 0.120 |
Why?
| | Horner Syndrome | 1 | 2015 | 3 | 0.120 |
Why?
| | Phenylephrine | 1 | 2015 | 36 | 0.120 |
Why?
| | Ophthalmic Solutions | 1 | 2015 | 20 | 0.120 |
Why?
| | Enoxaparin | 1 | 2015 | 30 | 0.120 |
Why?
| | Heparin | 1 | 2015 | 88 | 0.110 |
Why?
| | Imidazoles | 1 | 2015 | 124 | 0.110 |
Why?
| | Warfarin | 1 | 2015 | 83 | 0.110 |
Why?
| | Treatment Outcome | 1 | 2024 | 5407 | 0.110 |
Why?
| | Infant | 2 | 2019 | 3684 | 0.110 |
Why?
| | Head Injuries, Closed | 1 | 2013 | 7 | 0.110 |
Why?
| | Eye Injuries | 1 | 2013 | 24 | 0.100 |
Why?
| | Metals | 1 | 2013 | 35 | 0.100 |
Why?
| | Stroke | 1 | 2018 | 509 | 0.100 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2013 | 62 | 0.100 |
Why?
| | Retinal Diseases | 1 | 2013 | 56 | 0.100 |
Why?
| | Device Removal | 1 | 2013 | 82 | 0.100 |
Why?
| | Anticoagulants | 1 | 2015 | 267 | 0.090 |
Why?
| | Endoscopy | 1 | 2013 | 123 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 1543 | 0.090 |
Why?
| | Prospective Studies | 1 | 2017 | 2428 | 0.090 |
Why?
| | Methylprednisolone | 1 | 2018 | 41 | 0.040 |
Why?
| | Spinal Puncture | 1 | 2018 | 17 | 0.040 |
Why?
| | Phlebography | 1 | 2018 | 55 | 0.040 |
Why?
| | Surgical Flaps | 1 | 2018 | 110 | 0.030 |
Why?
| | Visual Acuity | 1 | 2018 | 144 | 0.030 |
Why?
| | Disease Progression | 1 | 2018 | 870 | 0.030 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2013 | 11 | 0.030 |
Why?
| | Fundus Oculi | 1 | 2013 | 24 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2013 | 108 | 0.020 |
Why?
|
|
Pemberton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|